Abstract:
BACKGROUND:Although naratriptan is not approved for prophylactic use in migraine, naratriptan has been shown to be significantly more effective than placebo for short-term prevention of menstrually related migraine (MRM). The tolerability of naratriptan administered intermittently for prophylaxis for MRM over the long term has not been assessed. OBJECTIVE:To assess the tolerability of naratriptan 1 mg given twice daily for 6 days per month, administered for up to 1 year for short-term prevention of MRM in an open-label study. METHODS:Patients were eligible for the study if they were between 18 and 65 years of age and had at least a 1-year history of migraine, with or without aura, as defined by 1988 International Headache Society criteria; reported a history of MRM; and had at least 1 MRM attack during their last menstrual cycle. MRM was defined as any migraine beginning during the perimenstrual period (PMP). By definition, the PMP consisted of Days -2, -1, 1, 2, 3, and 4, with Day 1 being the first day of menstrual flow. During each menstrual cycle occurring over a 1-year period, patients began short-term treatment with naratriptan 1 mg twice daily (BID) 3 days before the expected onset of MRM and treated for a total of 6 days. Naratriptan 2.5 mg could be taken for breakthrough MRM attacks. Tolerability and safety measures included adverse events, standard clinical laboratory tests, electrocardiograms (ECGs), and vital signs. The secondary endpoints were the percentage of PMPs without MRM; headache disability as measured by the Headache Impact Test (HIT), and psychological health as measured by the Beck Depression Inventory version 2 (BDI-II). RESULTS:The number of patients who took at least 1 dose of study medication (safety population) was 457, and the numbers of patients completing 6 months and 12 months of treatment were 318 and 131, respectively. Note that 171 (37%) patients were asked to leave the study once target enrollment numbers were met. The only adverse event occurring at an incidence of more than 2% during the 6-day treatment periods when naratriptan 1 mg BID was taken with or without an additional 2.5-mg dose for breakthrough attacks was ear, nose, throat infection (3%). No specific adverse event considered at least possibly to be related to study medication occurred in more than 2% of patients. No serious drug-related adverse events were reported. Furthermore, no patient experienced clinically relevant drug-related changes in 12-lead ECGs, vital signs, or clinical laboratory tests. Patients in both the 6- and 12-month populations did not experience an MRM in approximately 50% of treated PMPs. Health outcomes results suggested that naratriptan reduced headache impact when used for up to 12 months for the short-term prevention of MRM. CONCLUSION:Naratriptan 1 mg BID, with the optional use of an additional 2.5-mg dose for breakthrough attacks, was well tolerated when used for 6 continuous days per month for up to 1 year for short-term prevention of MRM.
journal_name
Headachejournal_title
Headacheauthors
Brandes JL,Smith T,Diamond M,Ames MHdoi
10.1111/j.1526-4610.2007.00809.xsubject
Has Abstractpub_date
2007-06-01 00:00:00pages
886-94issue
6eissn
0017-8748issn
1526-4610pii
HED809journal_volume
47pub_type
临床试验,杂志文章相关文献
HEADACHE文献大全abstract:BACKGROUND:Oxygen and triptans are drugs of first choice to abort cluster headache attacks. However, clinical predictors of treatment response are unavailable. OBJECTIVE:We aimed to identify predictors of acute treatment response among patients with cluster headache. METHODS:We investigated 246 cluster headache patie...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/j.1526-4610.2007.00862.x
更新日期:2007-07-01 00:00:00
abstract::This study examined the relationship between the menstrual cycle, the stress process, and migraines. Women migraineurs (N = 12) and a matched control sample (N = 12) completed a set of questionnaires assessing stress, appraisal, and coping at premenses, menses, and ovulation. In addition, migraineurs completed a month...
journal_title:Headache
pub_type: 杂志文章
doi:10.1046/j.1526-4610.1996.3609531.x
更新日期:1996-10-01 00:00:00
abstract::Traditionally, episodic primary headache disorders are characterized by a return of preheadache (normal) neurologic function between episodes of headache. In contrast, patients with chronic headache often do not return to normal neurologic function between headache attacks. This article proposes that the evolution fro...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/j.1526-4610.2004.04094.x
更新日期:2004-05-01 00:00:00
abstract::A serologically proven case of parainfluenza viral infection was associated with the onset and disappearance of cluster headache. The patient had long-standing migraine that ceased during the cluster headache period and recurred when the latter stopped. Possibly, the virus was neurally transmitted to the trigeminal-au...
journal_title:Headache
pub_type: 杂志文章
doi:10.1046/j.1526-4610.1998.3802132.x
更新日期:1998-02-01 00:00:00
abstract:OBJECTIVE:To compare the efficacy of mouth-dispersible aspirin 900 mg and placebo in the treatment of migraine. BACKGROUND:Aspirin is widely accepted as an effective therapy for migraine. Previous studies have indicated that gastric stasis and delayed gastric emptying, which occur during migraine attacks, delay aspiri...
journal_title:Headache
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1046/j.1526-4610.2002.02076.x
更新日期:2002-04-01 00:00:00
abstract::A 29-year-old woman presented with acute hemicrania, trigeminal neuropathy and posterior fossa dysfunction. The admission differential diagnosis included vertebral artery dissection, posterior circulation aneurysm, vascular malformation and brainstem infarction. However, radiographic and CSF studies indicated demyelin...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/j.1526-4610.1989.hed2907423.x
更新日期:1989-07-01 00:00:00
abstract::If you vomit with migraines, get full-blown migraines upon awakening, or want rapid relief without injections, consider a nasal spray. Options include triptans (zolmitriptan [Zomig] or sumatriptan [Imitrex]), DHE (Migranal), or an NSAID (Sprix). ...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/head.12045
更新日期:2013-03-01 00:00:00
abstract:BACKGROUND AND OBJECTIVES:The objective of this study was to investigate the prevalence and sociodemographic characteristics of headaches among Turkish adolescents aged 12 to 17 years old in Bursa province of Turkey. METHODS:A multistep, stratified, cluster sampling method was used for subject selection. The estimated...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/j.1526-4610.2006.00362.x
更新日期:2006-04-01 00:00:00
abstract:OBJECTIVE:Previous attempts to develop a pragmatic human model for testing new anti-migraine drugs, have failed. Calcitonin gene-related peptide (CGRP) induces a mild headache in healthy volunteers and migraine-like headache in migraine patients. The induced headache must respond to already established migraine treatme...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/head.13747
更新日期:2020-04-01 00:00:00
abstract:OBJECTIVE:To determine the pharmacological profile of frovatriptan. BACKGROUND:Frovatriptan is a new 5-HT(1B/1D) agonist developed for the treatment of migraine. METHODS:Pharmacological studies were performed using in vitro and in vivo techniques. RESULTS:Radioligand-binding studies showed that frovatriptan has a hi...
journal_title:Headache
pub_type: 杂志文章
doi:10.1046/j.1526-4610.42.s2.2.x
更新日期:2002-04-01 00:00:00
abstract::Fourteen female volunteers who met diagnostic criteria for migraine headache monitored their headache activity and menstrual distress symptoms for one menstrual cycle. Serum estradiol and progesterone levels, and menstrual distress measures were collected at four points of the menstrual cycle: menstrual, ovulatory, lu...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/j.1526-4610.1992.hed3206292.x
更新日期:1992-06-01 00:00:00
abstract:PURPOSE:Migraine is an exclusively human chronic disorder with ictal manifestations characterized by a multifaceted clinical complexity pointing to a cerebral cortical involvement. The present review is aimed to cover the clinical, neuroimaging, and neurophysiological literature on the role of the cerebral cortex in mi...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/head.13935
更新日期:2020-10-01 00:00:00
abstract::Paroxysmal headaches often occur in benign headache disorders such as episodic cluster headache, chronic paroxysmal hemicrania (CPH) and episodic paroxysmal hemicrania. We report 2 patients with paroxysmal headaches occurring in association with cerebrovascular disease. The first patient had paroxysmal headaches from ...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/j.1526-4610.1992.hed3202075.x
更新日期:1992-02-01 00:00:00
abstract::Questions about discomfort or pain produced by various stimuli (e.g., light, sound, exercise, neck movements) are currently used to differentiate between various primary headache disorders. In order to evaluate the usefulness of differences in sensitivity to physical stimuli in headache diagnosis, the answers to a que...
journal_title:Headache
pub_type: 杂志文章
doi:10.1046/j.1526-4610.1999.3908552.x
更新日期:1999-09-01 00:00:00
abstract:OBJECTIVE:We aimed to investigate (1) to which extent headache diary variables correlate among each other; (2) to which extent they correlate with generic measures of quality of life and disability; (3) and whether correlations vary over time. METHODS:We performed a secondary analysis of data from 301 patients sufferi...
journal_title:Headache
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1111/j.1526-4610.2009.01434.x
更新日期:2009-06-01 00:00:00
abstract:OBJECTIVES:Migraine is a common disabling neurological disorder. Current acute treatments for migraine in adolescents are mostly pharmacological and may have limited effectiveness, can cause side effects, and may lead to medication overuse. There is an unmet need for effective and well-tolerated treatments. Remote elec...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/head.14042
更新日期:2020-12-21 00:00:00
abstract::This paper describes the development and validation of a migraine-specific quality-of-life instrument that is capable of measuring health-related quality-of-life impairments attributed to migraine. Item selection, item reduction, and pretesting and finalization of items during the instrument development phase resulted...
journal_title:Headache
pub_type: 杂志文章
doi:10.1046/j.1526-4610.1998.3804295.x
更新日期:1998-04-01 00:00:00
abstract:BACKGROUND:A vascular component in ergotamine-induced headache has been proposed. No study has been carried out to evaluate cerebral hemodynamic changes by means of transcranial Doppler during withdrawal from migraine medication; in particular, ergotamine-containing drugs. METHOD:We examined 21 patients suffering from...
journal_title:Headache
pub_type: 杂志文章
doi:10.1046/j.1526-4610.1998.3809679.x
更新日期:1998-10-01 00:00:00
abstract::Orthostatic headache is a key symptom of intracranial hypotension; however, not all orthostatic headaches are caused by cerebrospinal fluid leaks leading to intracranial hypotension. We report here the unusual case of a 68-year-old man presenting with orthostatic headache in which compression of the C3 spinal nerve ro...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/j.1526-4610.2007.00982.x
更新日期:2008-01-01 00:00:00
abstract:OBJECTIVE:To examine the disability, health care resource utilization, and direct annual costs among patients with migraine, categorized according to the number of headache days experienced in the past month. BACKGROUND:Migraine exists on a continuum of different attack frequencies and associated levels of disability....
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/head.13421
更新日期:2018-11-01 00:00:00
abstract:OBJECTIVE:To evaluate the efficacy of ubrogepant on patient-reported functional disability, satisfaction with study medication, and global impression of change. BACKGROUND:Ubrogepant is a small-molecule, oral calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine. In 2 phase ...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/head.13766
更新日期:2020-04-01 00:00:00
abstract::After taking both conventional oral rizatriptan tablets and oral disintegrating rizatriptan tablets in the treatment of migraine with or without aura, patients were permitted to select their formulation preference. All adult patients who had requested continuation of rizatriptan during a 6-month period were included i...
journal_title:Headache
pub_type: 杂志文章
doi:10.1046/j.1526-4610.2000.00055.x
更新日期:2000-05-01 00:00:00
abstract::Significant progress in molecular genetics has advanced our understanding of the genetic basis of migraine. The fundamentals of molecular genetics, and the recent advances in the field, are important for clinicians to understand, as they provide a foundation for critical appraisal of the literature, unprecedented insi...
journal_title:Headache
pub_type: 杂志文章,评审
doi:10.1111/head.12156
更新日期:2013-09-01 00:00:00
abstract::A person's response to pain treatment may be due to factors other than the direct effect of analgesics. Amelioration of pain is often associated with modalities that appear to make no scientific sense. This review outlines the mechanisms of pain amelioration other than that by medication. These mechanisms help to expl...
journal_title:Headache
pub_type: 杂志文章
doi:10.1046/j.1526-4610.2002.02155.x
更新日期:2002-07-01 00:00:00
abstract::A variety of drugs from diverse pharmacological classes are in use for migraine prevention. Traditionally, they have been discovered by serendipity. Examples include beta-adrenergic blockers, anticonvulsants, tricyclic antidepressants, and serotonin receptor antagonists. The mechanisms of action of migraine preventive...
journal_title:Headache
pub_type: 杂志文章,评审
doi:10.1111/j.1526-4610.2007.00677.x
更新日期:2007-04-01 00:00:00
abstract:OBJECTIVE:To evaluate whether self-reported past migraine response to reproductive life events (menses, pregnancy, menopause) alters the likelihood of worsening of migraine with exogenous hormone use. METHODS:A retrospective study was conducted on 451 female patients at the University Headache Center who had a diagnos...
journal_title:Headache
pub_type: 杂志文章
doi:10.1046/j.1526-4610.2000.00027.x
更新日期:2000-03-01 00:00:00
abstract::Ischemic colitis has not been reported in association with naratriptan therapy. We describe the occurrence of ischemic colitis in a patient who was treated with abortive doses of naratriptan for migraine and was also taking long-term oral contraceptives. Concurrent use of naratriptan and oral contraceptives should pro...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/j.1526-4610.2005.05077_4.x
更新日期:2005-04-01 00:00:00
abstract::Several second-generation triptans have been introduced that differ in their pharmacologic profiles relative to each other and to sumatriptan. As therapeutic options multiply, clinicians must be able to distinguish among these compounds. Recently, a meta-analysis was conducted on data from 53 double-blind, randomized,...
journal_title:Headache
pub_type: 杂志文章
doi:10.1046/j.1526-4610.2002.0420s1018.x
更新日期:2002-01-01 00:00:00
abstract::Head pain is the fifth most common reason for emergency department (ED) visits. It is second only to focal weakness as the most common reason for neurological consultation in the ED. This manuscript reviews how patients with migraine, the most common primary headache disorder for which patients seek medical treatment,...
journal_title:Headache
pub_type: 杂志文章,评审
doi:10.1111/head.12399
更新日期:2014-07-01 00:00:00
abstract::Two cases of baroreflex failure presented with tension-type/exertional headache. The usefulness of noninvasive physiological tests in diagnosing baroreflex failure and the role of baroreceptors in trigeminal nociception are discussed. ...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/j.1526-4610.2006.00514_3.x
更新日期:2006-07-01 00:00:00